Shaheen Group secures 500 MBBS seats for Indian students in Tajikistan
As part of the collaboration, the Ambassador of Tajikistan to India, along with the Cultural Ambassador and other diplomatic representatives, visited the Shaheen Campus. Dr Zainab, the Tajikistan coordinator, assured that full security is provided to international students there.
Dr Abdul Qadeer, Chairman of the Shaheen Group of Institutions, explained that this agreement offers such students a chance to fulfill their dream of becoming doctors.
He further stated that students can complete the entire six-year MBBS course, including hostel accommodation and Indian food, for just Rs 32 lakh.
Dr Qadeer shared that the course fee can be paid in easy installments. The registration fee is Rs 49,500, and registrations will remain open until the end of June. The Rs 32 lakh package also includes insurance coverage.
In a significant move, Shaheen Group and its medical partners will provide FMGE (Foreign Medical Graduate Examination) coaching from the first day of the MBBS course. This ensures that students are well-prepared to obtain a license for medical practice after graduation. For more information, visit: www.msitshaheen.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
Man denied mediclaim over Google Maps mismatch: Here's all you need to know
In a rare but telling case, a Gujarat resident's health insurance claim was rejected because his Google Timeline didn't match the hospital location. According to a PTI report, Vallabh Matka from Silvassa was admitted to a hospital in September 2024 for viral pneumonia and later denied reimbursement by Go Digit General Insurance, which flagged discrepancies between his statement and his phone's location data. The Valsad district consumer forum ruled in Matka's favour this month, noting that the insurer had no justifiable grounds and must settle Rs 48,251 with 8 per cent interest. Can insurers legally reject claims using Google data? 'Insurers can reject a claim based on Google Timeline, but only under strict conditions,' said Hari Radhakrishnan, expert at the Insurance Brokers Association of India (IBAI). 'The data must be lawfully obtained with informed consent under India's digital data protection laws and should decisively support the insurer's claim. But mobile phones can be used by others, so the data often needs corroboration,' he said. Anita Teli, chief compliance officer at Probus Insurance, clarified that digital data cannot be treated as standalone proof. 'Insurers must rely on medical records, bills, and discharge summaries. Digital tools may support a fraud investigation but aren't legally admissible as sole evidence,' Teli said. How policyholders can protect themselves Teli advised policyholders to keep full documentation, including prescriptions, hospital admission records, and discharge papers. 'Make sure you notify your insurer upon hospitalisation and avoid any mismatches in submitted forms,' she said. Radhakrishnan added that consumers should understand data-sharing implications before granting access to personal digital information. 'If you suspect misuse, raise a grievance with the insurer. If unresolved, escalate to the ombudsman,' he said. Is this part of a broader trend? Both experts agree that insurers are increasingly using digital tools to detect fraud, but not for blanket claim denials. 'There have been cases where Google data was used to disprove someone's presence at an accident site,' Radhakrishnan noted. But Teli clarified these are exceptions, not the norm. What to do if your claim is wrongly denied Consumers have multiple channels for redressal. 'Start with the insurer's grievance redressal team,' said Teli. 'If the issue persists, register on the Irdai's Grievance Management System or approach the Insurance Ombudsman.' While consumer forums offer recourse, Radhakrishnan cautioned that they are often burdened with cases, making resolution slow.
Mint
an hour ago
- Mint
New IPO: NephroPlus files papers with Sebi for ₹353.4 crore IPO to expand Dialysis clinics
Nephrocare Health Services Limited, widely recognized under the brand name NephroPlus, has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) to raise ₹353.4 crore through an initial public offering (IPO). The Hyderabad-based company plans to use the proceeds to expand its network of dialysis clinics across India and repay outstanding debt, with the balance allocated to general corporate purposes. Advertisement The IPO will include a fresh issue of equity shares worth ₹353.4 crore and an offer-for-sale (OFS) of up to 1.27 crore equity shares by promoter and non-promoter shareholders. Among the OFS participants are Investcorp Private Equity Fund II, Healthcare Parent Limited, Edoras Investment Holdings Pte. Ltd., and 360 One Special Opportunities Fund. The company may also consider a pre-IPO placement of up to ₹70.6 crore, which would reduce the size of the fresh issue accordingly. Asia's Largest Dialysis Service Provider Established in 2009, NephroPlus has emerged as Asia's largest dialysis services provider and the fifth-largest globally in terms of the number of treatments performed in FY25, according to a Frost & Sullivan report. As of now, the company operates 447 clinics across 269 cities in 21 Indian states and 4 Union Territories, serving over 33,000 patients annually. NephroPlus commands more than 50 percent revenue market share in India's organised dialysis services market. Advertisement NephroPlus has also made a significant push into international markets. It currently operates 34 clinics in the Philippines, 5 in Nepal, 4 in Uzbekistan, and recently entered Saudi Arabia in a bid to tap the Middle East healthcare market. The company's promoters include Vikram Vuppala, BVP Trust (Bessemer Venture Partners), and Investcorp-affiliated entities. Proceeds to Fuel Domestic Expansion As per the DRHP, NephroPlus will allocate ₹129.1 crore from the fresh issue proceeds towards setting up new dialysis clinics in India, which aligns with its strategy to grow its domestic footprint. An additional ₹136 crore will be used to pre-pay or repay certain existing borrowings, enhancing the company's financial flexibility and improving its balance sheet. Advertisement In FY25, the company reported ₹755.8 crore in revenue from operations and a profit after tax of ₹67 crore, reflecting robust growth amid increasing demand for kidney care services. With chronic kidney disease (CKD) rising as the third fastest-growing cause of death globally, and diabetes and hypertension being its primary drivers, NephroPlus is well-positioned to benefit from secular health trends. ICICI Securities, Ambit Private Limited, IIFL Capital Services, and Nomura Financial Advisory and Securities (India) are acting as Book Running Lead Managers (BRLMs) for the IPO. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions. Advertisement
NDTV
an hour ago
- NDTV
Infant Loses 5 Fingers, Chennai Hospital Ordered To Pay Compensation
Chennai: The Chennai North District Consumer Disputes Redressal Commission has directed a hospital and a doctor, here, to provide compensation of Rs 23.65 lakh spent on treatment, besides Rs 10 lakh for pain and suffering caused after a 24-week-old boy lost five fingers allegedly due to gangrene. The Commission held the city hospital and the gynaecologist liable for negligence and directed them to pay the compensation and also Rs 10,000 towards the cost of litigation, recently. It said the hospital and the doctor 'failed to justify the emergency nature of the procedure or explain why consent was bypassed.' The boy's premature birth was reportedly caused by a cervical pessary procedure (non-invasive insertion of a silicone ring in the vagina to support the cervix) without obtaining due consent. The procedure led to the boy developing gangrene, and the Commission held that the premature insertion done without testing or emergency need led to complications, including preterm delivery at 24 weeks. The baby's mother was undergoing fertility treatment, and she was 22 weeks pregnant when the device was inserted. It was said that during post-delivery and transfer to the NICU, the baby developed early signs of gangrene. As a result, all five fingers of his right hand were amputated.
